Cargando…

Biological Evaluation of [(18)F]AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma

Purpose: N-(2-[(18)F]fluoropropionyl)-L-glutamate ([(18)F]FPGLU) for hepatocellular carcinoma (HCC) imaging has been performed in our previous studies, but its radiosynthesis method and stability in vivo need to be improved. Hence, we evaluated the synthesis and biological properties of a simple [(1...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Liping, Xiang, Xianhong, Su, Shu, Liu, Shaoyu, Xiong, Ying, Ma, Hui, Yuan, Gongjun, Nie, Dahong, Tang, Ganghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085524/
https://www.ncbi.nlm.nih.gov/pubmed/33937189
http://dx.doi.org/10.3389/fchem.2021.630452
_version_ 1783686359481843712
author Lin, Liping
Xiang, Xianhong
Su, Shu
Liu, Shaoyu
Xiong, Ying
Ma, Hui
Yuan, Gongjun
Nie, Dahong
Tang, Ganghua
author_facet Lin, Liping
Xiang, Xianhong
Su, Shu
Liu, Shaoyu
Xiong, Ying
Ma, Hui
Yuan, Gongjun
Nie, Dahong
Tang, Ganghua
author_sort Lin, Liping
collection PubMed
description Purpose: N-(2-[(18)F]fluoropropionyl)-L-glutamate ([(18)F]FPGLU) for hepatocellular carcinoma (HCC) imaging has been performed in our previous studies, but its radiosynthesis method and stability in vivo need to be improved. Hence, we evaluated the synthesis and biological properties of a simple [(18)F]-labeled glutamate analog, [(18)F]AlF-1,4,7-triazacyclononane-1,4,7-triacetic-acid-2-S-(4-isothiocyanatobenzyl)-l-glutamate ([(18)F]AlF-NOTA-NSC-GLU), for HCC imaging. Procedures: [(18)F]AlF-NOTA-NSC-GLU was synthesized via a one-step reaction sequence from NOTA-NSC-GLU. In order to investigate the imaging value of [(18)F]AlF-NOTA-NSC-GLU in HCC, we conducted positron emission tomography/computed tomography (PET/CT) imaging and competitive binding of [(18)F]AlF-NOTA-NSC-GLU in human Hep3B tumor-bearing mice. The transport mechanism of [(18)F]AlF-NOTA-NSC-GLU was determined by competitive inhibition and protein incorporation experiments in vitro. Results: [(18)F]AlF-NOTA-NSC-GLU was prepared with an overall radiochemical yield of 29.3 ± 5.6% (n = 10) without decay correction within 20 min. In vitro competitive inhibition experiments demonstrated that the Na(+)-dependent systems [Formula: see text] , B0(+), ASC, and minor [Formula: see text] were involved in the uptake of [(18)F]AlF-NOTA-NSC-GLU, with the Na(+)-dependent system [Formula: see text] possibly playing a more dominant role. Protein incorporation studies of the Hep3B human hepatoma cell line showed almost no protein incorporation. Micro-PET/CT imaging with [(18)F]AlF-NOTA-NSC-GLU showed good tumor-to-background contrast in Hep3B human hepatoma-bearing mouse models. After [(18)F]AlF-NOTA-NSC-GLU injection, the tumor-to-liver uptake ratio of [(18)F]AlF-NOTA-NSC-GLU was 2.06 ± 0.17 at 30 min post-injection. In vivo competitive binding experiments showed that the tumor-to-liver uptake ratio decreased with the addition of inhibitors to block the X(AG) system. Conclusions: We have successfully synthesized [(18)F]AlF-NOTA-NSC-GLU as a novel PET tracer with good radiochemical yield and high radiochemical purity. Our findings indicate that [(18)F]AlF-NOTA-NSC-GLU may be a potential candidate for HCC imaging. Also, a further biological evaluation is underway.
format Online
Article
Text
id pubmed-8085524
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80855242021-05-01 Biological Evaluation of [(18)F]AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma Lin, Liping Xiang, Xianhong Su, Shu Liu, Shaoyu Xiong, Ying Ma, Hui Yuan, Gongjun Nie, Dahong Tang, Ganghua Front Chem Chemistry Purpose: N-(2-[(18)F]fluoropropionyl)-L-glutamate ([(18)F]FPGLU) for hepatocellular carcinoma (HCC) imaging has been performed in our previous studies, but its radiosynthesis method and stability in vivo need to be improved. Hence, we evaluated the synthesis and biological properties of a simple [(18)F]-labeled glutamate analog, [(18)F]AlF-1,4,7-triazacyclononane-1,4,7-triacetic-acid-2-S-(4-isothiocyanatobenzyl)-l-glutamate ([(18)F]AlF-NOTA-NSC-GLU), for HCC imaging. Procedures: [(18)F]AlF-NOTA-NSC-GLU was synthesized via a one-step reaction sequence from NOTA-NSC-GLU. In order to investigate the imaging value of [(18)F]AlF-NOTA-NSC-GLU in HCC, we conducted positron emission tomography/computed tomography (PET/CT) imaging and competitive binding of [(18)F]AlF-NOTA-NSC-GLU in human Hep3B tumor-bearing mice. The transport mechanism of [(18)F]AlF-NOTA-NSC-GLU was determined by competitive inhibition and protein incorporation experiments in vitro. Results: [(18)F]AlF-NOTA-NSC-GLU was prepared with an overall radiochemical yield of 29.3 ± 5.6% (n = 10) without decay correction within 20 min. In vitro competitive inhibition experiments demonstrated that the Na(+)-dependent systems [Formula: see text] , B0(+), ASC, and minor [Formula: see text] were involved in the uptake of [(18)F]AlF-NOTA-NSC-GLU, with the Na(+)-dependent system [Formula: see text] possibly playing a more dominant role. Protein incorporation studies of the Hep3B human hepatoma cell line showed almost no protein incorporation. Micro-PET/CT imaging with [(18)F]AlF-NOTA-NSC-GLU showed good tumor-to-background contrast in Hep3B human hepatoma-bearing mouse models. After [(18)F]AlF-NOTA-NSC-GLU injection, the tumor-to-liver uptake ratio of [(18)F]AlF-NOTA-NSC-GLU was 2.06 ± 0.17 at 30 min post-injection. In vivo competitive binding experiments showed that the tumor-to-liver uptake ratio decreased with the addition of inhibitors to block the X(AG) system. Conclusions: We have successfully synthesized [(18)F]AlF-NOTA-NSC-GLU as a novel PET tracer with good radiochemical yield and high radiochemical purity. Our findings indicate that [(18)F]AlF-NOTA-NSC-GLU may be a potential candidate for HCC imaging. Also, a further biological evaluation is underway. Frontiers Media S.A. 2021-04-16 /pmc/articles/PMC8085524/ /pubmed/33937189 http://dx.doi.org/10.3389/fchem.2021.630452 Text en Copyright © 2021 Lin, Xiang, Su, Liu, Xiong, Ma, Yuan, Nie and Tang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Chemistry
Lin, Liping
Xiang, Xianhong
Su, Shu
Liu, Shaoyu
Xiong, Ying
Ma, Hui
Yuan, Gongjun
Nie, Dahong
Tang, Ganghua
Biological Evaluation of [(18)F]AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma
title Biological Evaluation of [(18)F]AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma
title_full Biological Evaluation of [(18)F]AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma
title_fullStr Biological Evaluation of [(18)F]AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma
title_full_unstemmed Biological Evaluation of [(18)F]AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma
title_short Biological Evaluation of [(18)F]AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma
title_sort biological evaluation of [(18)f]alf-nota-nsc-glu as a positron emission tomography tracer for hepatocellular carcinoma
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085524/
https://www.ncbi.nlm.nih.gov/pubmed/33937189
http://dx.doi.org/10.3389/fchem.2021.630452
work_keys_str_mv AT linliping biologicalevaluationof18falfnotanscgluasapositronemissiontomographytracerforhepatocellularcarcinoma
AT xiangxianhong biologicalevaluationof18falfnotanscgluasapositronemissiontomographytracerforhepatocellularcarcinoma
AT sushu biologicalevaluationof18falfnotanscgluasapositronemissiontomographytracerforhepatocellularcarcinoma
AT liushaoyu biologicalevaluationof18falfnotanscgluasapositronemissiontomographytracerforhepatocellularcarcinoma
AT xiongying biologicalevaluationof18falfnotanscgluasapositronemissiontomographytracerforhepatocellularcarcinoma
AT mahui biologicalevaluationof18falfnotanscgluasapositronemissiontomographytracerforhepatocellularcarcinoma
AT yuangongjun biologicalevaluationof18falfnotanscgluasapositronemissiontomographytracerforhepatocellularcarcinoma
AT niedahong biologicalevaluationof18falfnotanscgluasapositronemissiontomographytracerforhepatocellularcarcinoma
AT tangganghua biologicalevaluationof18falfnotanscgluasapositronemissiontomographytracerforhepatocellularcarcinoma